4.7 Article

Genetic studies reveal an unexpected negative regulatory role for Jak2 in thrombopoiesis

Related references

Note: Only part of the references are listed.
Article Multidisciplinary Sciences

Mpl expression on megakaryocytes and platelets is dispensable for thrombopoiesis but essential to prevent myeloproliferation

Ashley P. Ng et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)

Review Pharmacology & Pharmacy

Investigational Janus kinase inhibitors

Constantine S. Tam et al.

EXPERT OPINION ON INVESTIGATIONAL DRUGS (2013)

Article Multidisciplinary Sciences

Platelet-biased stem cells reside at the apex of the haematopoietic stem-cell hierarchy

Alejandra Sanjuan-Pla et al.

NATURE (2013)

Article Medicine, General & Internal

A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis

Srdan Verstovsek et al.

NEW ENGLAND JOURNAL OF MEDICINE (2012)

Article Medicine, General & Internal

JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis

Claire Harrison et al.

NEW ENGLAND JOURNAL OF MEDICINE (2012)

Article Multidisciplinary Sciences

Lineage Tracing of Pf4-Cre Marks Hematopoietic Stem Cells and Their Progeny

Simon D. J. Calaminus et al.

PLOS ONE (2012)

Article Medicine, General & Internal

JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis

Linda M. Scott et al.

NEW ENGLAND JOURNAL OF MEDICINE (2007)

Article Medicine, General & Internal

MPLW515L is anovel somatic activating mutation in myelofibrosis with myeloid metaplasia

Yana Pikman et al.

PLOS MEDICINE (2006)

Article Medicine, General & Internal

A gain-of-function mutation of JAK2 in myeloproliferative disorders

R Kralovics et al.

NEW ENGLAND JOURNAL OF MEDICINE (2005)

Article Medicine, General & Internal

Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders

EJ Baxter et al.

LANCET (2005)